Arterial spin-labeling evaluation of cerebrovascular reactivity to acetazolamide in healthy subjects.

BACKGROUND AND PURPOSE

Arterial spin-labeling MR imaging permits safe, repeated CBF measurement. We investigated the potential and technical factors of arterial spin-labeling imaging in assessing cerebrovascular reactivity to acetazolamide.

MATERIALS AND METHODS

The regional CBF was measured in 8 healthy volunteers by use of a 3D pseudocontinuous arterial spin-labeling sequence. Arterial spin labeling imaging was performed at rest and every 2 minutes after intravenous acetazolamide injection. To evaluate repeatability, regional CBF measurements were repeated without acetazolamide within an imaging session and on a separate day. Additionally, arterial spin-labeling imaging was performed at rest and after acetazolamide injection with different postlabeling delays, and regional cerebrovascular reactivity was calculated.

RESULTS

The regional CBF started to increase immediately after acetazolamide injection and peaked at approximately 10 minutes, followed by a slow decrease. Favorable intrasession repeatability was demonstrated, especially when scanner tuning was omitted between scans. Rest regional CBF was slightly lower with a postlabeling delay of 2525 ms than with a postlabeling delay of 1525 ms, and the postlabeling delay-dependent difference was more evident for regional CBF after acetazolamide injection and regional cerebrovascular reactivity.

CONCLUSIONS

Arterial spin-labeling imaging allows evaluation of the distribution, magnitude, and time course of cerebrovascular response to acetazolamide. The influence of the postlabeling delay on the estimated cerebrovascular reactivity should be noted.